ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease

Previous studies identified the Ser/Thr protein kinase, AKT, as a therapeutic target in thrombo-inflammatory diseases. Here we report that specific inhibition of AKT with ARQ 092, an orally-available AKT inhibitor currently in phase Ib clinical trials as an anti-cancer drug, attenuates the adhesive...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Kim, Kyungho, Li, Jing, Barazia, Andrew, Tseng, Alan, Youn, Seock-Won, Abbadessa, Giovanni, Yu, Yi, Schwartz, Brian, Andrews, Robert K., Gordeuk, Victor R., Cho, Jaehyung
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2017
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5286933/
https://ncbi.nlm.nih.gov/pubmed/27758820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.151159
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados